“Robust Sales of Proprietary Vaccines and Sanofi-Distributed Products”
Operating Loss of 123.5 Billion Won...Deficit Narrowed from Previous Year

SK Bioscience achieved top-line growth, driven by a turnaround to profitability at its subsidiary IDT Biologika and solid sales of its own vaccines and Sanofi-distributed product portfolio.

Exterior view of SK Bioscience Songdo Global R&PD Center. SK Bioscience

Exterior view of SK Bioscience Songdo Global R&PD Center. SK Bioscience

View original image

SK Bioscience announced in a disclosure on February 3 that its consolidated revenue for last year came in at 651.4 billion won, up 143.5% from a year earlier. The operating loss was 123.5 billion won, narrowing the deficit compared with the previous year. SK Bioscience stated, "Even in an environment of continued large-scale clinical trials, research and development (R&D), and production facility investments, we reduced our annual loss and laid the foundation for improved profitability."


Subsidiary IDT succeeded in turning a full-year profit just one year after its acquisition. IDT’s revenue last year was 465.7 billion won, up about 17% year-on-year, and it achieved 9.9 billion won in operating profit, successfully completing its turnaround. The company explained that strengthened partnerships with existing clients and productivity gains through process optimization played a decisive role.


SK Bioscience’s key proprietary vaccines also continued their upward sales trajectory, mainly in global markets. Despite downward pricing pressure from the shift of flu vaccine SKYCellflu to a trivalent formulation, export volumes to Latin America and Southeast Asia increased, allowing it to maintain solid growth.


The varicella vaccine SKYVaricella also increased its share of global exports, underpinned by a stable supply system through the Pan American Health Organization (PAHO). The herpes zoster vaccine SKYZoster is expanding its market share on the back of broader vaccination programs run by local governments in Korea, while at the same time pushing to expand exports, particularly in Asia.


Revenue from Sanofi products distributed domestically by SK Bioscience more than tripled compared with the previous year. Beyfortus, a respiratory syncytial virus (RSV) preventive monoclonal antibody injection launched last year, recorded near sell-out performance during the autumn and winter RSV season. The 6-in-1 combination vaccine Hexaxim and the Tdap (tetanus, diphtheria, pertussis) vaccine Adacel also supported revenue growth on the back of robust demand.


Meanwhile, SK Bioscience completed its move into the Songdo Global R&PD Center last month and is now operating an integrated, unified system that covers everything from research and development to commercialization readiness.


In particular, the company is focusing on securing key pipelines that will underpin its mid- to long-term growth. It is conducting global Phase 3 clinical trials in major markets such as the United States, Europe, and Korea for a 21-valent pneumococcal conjugate vaccine being co-developed with Sanofi, and is simultaneously preparing for global approvals and commercial production in line with the expansion of the Andong L House facility. The company expects the recently in-licensed "RSM01," a monoclonal antibody for RSV prevention introduced from Gates MRI under the Bill & Melinda Gates Foundation, to become a new core growth driver targeting a 6 trillion won market, backed by global exclusive supply rights.



An SK Bioscience official said, "This year, we plan to further advance the growth of our global contract development and manufacturing organization (CDMO) business centered on IDT, while accelerating the development of core pipelines based at the Songdo R&PD Center to secure mid- to long-term growth engines."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing